Cargando…

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia

BACKGROUND: Hyperuricemia cases (HU) can be classified into four subgroups by combining the two main causes of hyperuricemia, i.e. urate underexcretion and overproduction. These subgroups are as follows: underexcretion-type cases (UE); overproduction-type cases (OP); combined-type cases, and normal-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Toru, Nishi, Rie, Tanaka, Tuneo, Takagi, Kazutaka, Sakai, Katsuya, Takai, Mihoko, Morishima, Shigeru, Yamauchi, Takahiro, Ueda, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776396/ https://www.ncbi.nlm.nih.gov/pubmed/24052801 http://dx.doi.org/10.1159/000354029

Ejemplares similares

Quantitative Estimation of Urate Transport in Nephrons in Relation to Urinary Excretion Employing Benzbromarone-Loading Urate Clearance Tests in Cases of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2011)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

Decreased extra-renal urate excretion is a common cause of hyperuricemia
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia
por: Cabău, Georgiana, et al.
Publicado: (2019)

The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia
por: Wu, Liting, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Common UCP2 variants contribute to serum urate concentrations and the risk of hyperuricemia
por: Yang, Luyu, et al.
Publicado: (2016)

Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids
por: Marchetti, Marialaura, et al.
Publicado: (2016)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation
por: Takagi, Kazutaka, et al.
Publicado: (2011)

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
por: Yamauchi, Takahiro, et al.
Publicado: (2014)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Identification of GLUT12/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice
por: Toyoda, Yu, et al.
Publicado: (2020)

Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia
por: Ueno, Naohiko
Publicado: (2017)

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
por: Bove, Marilisa, et al.
Publicado: (2017)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats
por: Sung, Yoon-Young, et al.
Publicado: (2021)

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
por: Sharma, Gaurav, et al.
Publicado: (2021)

A Brief Review of Natural Products with Urate Transporter 1 Inhibition for the Treatment of Hyperuricemia
por: Yuan, Qianghua, et al.
Publicado: (2022)

The effects of URAT1/SLC22A12 nonfunctional variants,R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression
por: Sakiyama, Masayuki, et al.
Publicado: (2016)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase
por: Najjari, Abbas, et al.
Publicado: (2021)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
por: Zhao, Rui, et al.
Publicado: (2022)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008)

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
por: Pierzynowska, Kateryna, et al.
Publicado: (2020)

Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis
por: Li, Shu, et al.
Publicado: (2016)

Cordycepin, a Characteristic Bioactive Constituent in Cordyceps militaris, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice
por: Yong, Tianqiao, et al.
Publicado: (2018)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency
por: Wu, Mian, et al.
Publicado: (2021)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
por: Lee, Tao Han, et al.
Publicado: (2021)

Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway
por: Wang, Jen-Chun, et al.
Publicado: (2023)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function
por: Jeon, Hee Jung, et al.
Publicado: (2019)

Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis
por: Zhu, Junyu, et al.
Publicado: (2020)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
por: Toyoda, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7cvl38kno0njh0rj5l8fj0t28i